Leap Investments’s Atara Biotherapeutics ATRA Stock Holding History

Leap Investments’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$402K	Buy	1,104 +628	+132%	+$159K	0.26%	137
2020 Q1	$101K	Buy	+476	New	+$151K	0.15%	263
2019 Q3	–	Sell	-564	Closed	-$284K	–	405
2019 Q2	$284K	Buy	+564	New	+$398K	0.38%	102

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Leap Investments's ATRA Position: Q2 2020 in Review

Leap Investments increased its Atara Biotherapeutics (ATRA) stake by 132% in Q2 2020, buying an estimated $159K and bringing the position to 1,104 shares worth $402K. The position accounts for 0.26% of the portfolio, ranked #137.

Leap Investments first reported a position in ATRA in Q2 2019 and has held it in 3 quarters since. 122 funds tracked by Wall St. Rank hold ATRA as of Q2 2020.

Leap Investments held 1,104 shares of Atara Biotherapeutics worth $402K as of Q2 2020.
Leap Investments bought 628 Atara Biotherapeutics shares in Q2 2020, an estimated $159K.
Atara Biotherapeutics made up 0.26% of Leap Investments's portfolio in Q2 2020, its #137 holding.
Leap Investments first reported a position in Atara Biotherapeutics in Q2 2019 and has held it in 3 quarters since.
122 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.